Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results
Date:12/20/2007

)

(Unaudited)

Three months ended Nine months ended

September September September September

29, 30, 29, 30,

2007 2006 2007 2006

Revenues:

Net product sales $206,923 $168,951 $589,526 $528,571

Other product related

revenues 5,753 5,028 25,000 12,964

Total revenues 212,676 173,979 614,526 541,535

Cost of goods sold 146,248 118,919 403,854 382,540

Gross margin 66,428 55,060 210,672 158,995

Operating expenses:

Research and development 32,815 12,574 61,131 43,983

Selling, general and

administrative 33,910 40,053 100,466 111,337

Settlements, net (367) - (945) 1,250

Total operating expenses 66,358 52,627 160,652 156,570

Gain on sale of product rights - 3,054 20,000 3,054

Operating income 70 5,487 70,020 5,479

Other (expense) income, net - (38) (49) 66

Equity in loss of joint

venture (107) (18) (335) (497)

Loss on marketable

securities, net - - (4,643) (3,773)

Interest income 3,680 2,098 10,265 6,055

Interest expense (1,691) (1,681) (5,136) (5,069)

Income before provision for

income taxes 1,952 5,848 70,122 2,261

Provision for income taxes 683 1,461 24,541 565

Net income
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...andPressJoinEfforttoEducate ,, MEMPHIS,Tenn.,N...lBipolarFoundationandtheMedicAlertFoundationreceiv...m,whichisnowbeingwidelyacceptedasapreventivehealth...olarFoundationreceivedaproclamationofendorsementvi...isianaMitchLandrieu.TheNationalBipolarFoundationst...
(Date:11/25/2009)...simple question has been the focus of intense rese...lates High Blood Pressure in Mice & Men, Does str... has been the focus of intense research for many y...ablished a link between a novel gene, phosducin, a...s well as humans. The studies were directed by sci...
(Date:11/25/2009)...overlook needed care, study finds , , WE...pression can worsen her child,s asthma, U.S. resea...62 black mothers and their children found that chi...ad more frequent asthma symptoms, while children o...frequent asthma symptoms. , The Johns Hopkins C...
(Date:11/25/2009)...swire/--TheAmericanAssociationforHomecareendorsest...hisdesignedtosubstantiallyimprovetoolsandresources...ucedbySen.GeorgeLeMieux(R-Fla.). ,, TheLeMieuxb...forHomecareoutlinedinits13-pointanti-fraudactionpl....Thoseprovisionsincludecallingforreal-timeauditsan...
(Date:11/25/2009)...r in children with autism and related conditions c...medication combined with a structured training pro...earchers and their colleagues. , Published in t...ican Academy of Child and Adolescent Psychiatry , ...of Mental Health (NIMH) Research Units on Pediatri...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Mom's Depression May Worsen Child's Asthma 2Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2
...pot on Thursday United States fell short of its 20...Listeria by 50 percent.// The statistics relea...ion reveal that the rate of Listeria food poisoni...steria has started to climb because USDA hasn't es...
...pared by health officials in Tripura has brought t...he government// hospital that has claimed the live.... According to the report, submitted to the ...ia, low birth weight, septicemia, malaria, gastro ...
...ealth, John Hatzistergos, has confirmed that a new... a priority basis.// Stating that he has di...tart the detailed planning process for a new hospi...spital that is needed, and where it should be loca...
...tate of Volgograd, in Russia, has reported the dea...o reports from the state veterinary authorities.//...ly 11 regions in Southern Russia have reported Bir...25 hens that died in Volgograd, have tested positi...
...itled ‘Challenging Intellectual Property’ will be ...w York.// The Symposium will look into the a...ciated epitomes of knowledge production in economi... research and development, and enable affordable d...
...hundreds of patients who contracted Hepatitis C in...ing of their condition.// This is same as delayed ...ottish Blood Transfusion Service ,Frank McGuire, a... some had infected their partners. During ...
Other Medicine News:Health News:Government Hospital’s Poor Functioning Claims Lives Of 138 Infant 2Health News:Construction Of A New Hospital In The Bega Area Confirmed 2
(Date:11/25/2009)...Nov.25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ...f-carebloodanalysissystems,announcedtodaythatClint...entatthe21stAnnualPiperJaffrayHealthCareConference...cewillbeheldattheNewYorkPalaceHotelinNewYorkCity. ...resandmarketsportablebloodanalysissystemsforuseina...
(Date:11/25/2009)...ov.25/PRNewswire/--CempraPharmaceuticalsInc.todaya...executiveofficer,willpresentatthePiperJaffray21stA...009,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Fernan...tibioticclinicalprogramsforthetreatmentofdrug-resi...rmaceuticals ,, Foundedin2006,CempraPharmaceut...
(Date:11/25/2009)...ndSYDNEY,Nov.25/PRNewswire-FirstCall/--HeartWareIn...novatorandprovideroflessinvasive,miniaturizedcircu...ntofadvancedheartfailure,todayannouncedthatitissch...iperJaffrayHealthCareConferenceat8:00amESTonWednes...wYorkPalaceHotel,December1-2. ,, Alivewebcastof...
Breaking Medicine Technology:Evolution of a contraceptive for sea lamprey 8994 1Evolution of a contraceptive for sea lamprey 8994 2Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 49989 1Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 49989 2Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 49989 3Statement of Dr Elena Rios MD MSPH President and CEO National Hispanic Medical Association 49986 1
...: The Takeda Oncology,Company today reported the P...pany-sponsored Phase I/II study of VELCADE, dexame... in patients with previously untreated multiple,my... data showed that the,combination of four drugs wa...eived no prior therapies and response rates were e...
...aiichi Sankyo,Company, Limited (TSE: 4568), announ...III trial for DU-176b, an investigational oral Fac...tion. DU-176b is being developed,solely by Daiich...ctive Anticoagulation with Factor Xa Next,Generati...l compare DU-176b,with warfarin in preventing stro...
Other Medicine Technology:Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 2Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 3Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 4Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 5Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 6Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 2Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 3Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 4